Anti-TNF therapies and pregnancy: Outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register

Annals of the Rheumatic Diseases

Volumn 70, Issue 5, 2011, Pages 823-826

  Verstappen, Suzanne M M ^a   King, Yvonne ^a   Watson, Kath D ^a   Symmons, Deborah P M ^a   Hyrich, Kimme L ^a   Panayi, Gabriel ^b   Scott, David G I ^b   Bamji, Andrew ^b   Bax, Deborah ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CONCEPTION; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY OUTCOME; PRENATAL EXPOSURE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPONTANEOUS ABORTION; UNITED KINGDOM;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOGLOBULIN G; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79953330985     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.140822     Document Type: Article

References (20)

1. Skomsvoll JF, Wallenius M, Koksvik HS, et al. Drug insight: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation. Nat Clin Pract Rheumatol 2007;3:156-64. (Pubitemid 46416264)
2. Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009;36:635-41.
3. Hyrich KL, Symmons DP, Watson KD, et al. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 2006;54:2701-2. (Pubitemid 44205032)
4. th week of pregnancy: prospective study from general practice. BMJ 1997;315:32-4.
5. Blohm F, Fridén B, Milsom I. A prospective longitudinal population-based study of clinical miscarriage in an urban Swedish population. BJOG 2008;115:176-82; discussion 183.
6. Wilcox AJ, Weinberg CR, O'Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med 1988;319:189-94.
7. Berthelot JM, De Bandt M, Goupille P, et al. Exposition to anti-TNF drugs during pregnancy:outcome of 15 cases and review of the literature. Joint Bone Spine 2009;76:28-34.
8. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. J Rheumatol 2003;30:241-6. (Pubitemid 36152584)
9. Cush JJ. Biological drug use: US perspectives on indications and monitoring. Ann Rheum Dis 2005;64:iv18-23.
10. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21:733-8. (Pubitemid 40469001)
11. Kane S, Ford J, Cohen R, et al. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009;43:613-6.
12. Ostensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 2008;47:iii28-31.
13. Rosner I, Haddad A, Boulman N, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007;46:1508;author reply 1508-9.
14. Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007;46:695-8.
15. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99:2385-92. (Pubitemid 40039370)
16. Johnson DL, Jones KL, Chambers C. Pregnancy outcomes in women exposed to Adalimumab: OTIS autoimmune diseases in pregnancy project. Ann Rheum Dis 2008;58:S682.
17. Martínez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 2009;27:678-84.
18. de Man YA, Hazes JM, van der Heide H, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum 2009;60:3196-206.
19. Skomsvoll JF, Ostensen M, Irgens LM, et al. Pregnancy complications and delivery practice in women with connective tissue disease and inflammatory rheumatic disease in Norway. Acta Obstet Gynecol Scand 2000;79:490-5. (Pubitemid 30326131)
20. National Office for Statistics. Conceptions. 2010:http://www.statistics. gov.uk. (Data obtained 2009).